TNF and psoriasis: Antibodies against TNF-α (etanercept, adalimumab, and infliximab), IL-12 (ustekinumab), IL-23 (guselkumab, risankizumab, and tildrakizumab), IL-17A (secukinumab and ixekizumab), and IL-17AR (brodalumab) have shown clinical efficacy in improving skin and joint conditions [6] and are now indispensable for the treatment of psoriasis.